USANA Health Sciences Inc (USNA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
USANA Health Sciences Inc stock (USNA) is currently trading at $17.20. USANA Health Sciences Inc PE ratio is 29.33. USANA Health Sciences Inc PS ratio (Price-to-Sales) is 0.34. Analyst consensus price target for USNA is $39.00. WallStSmart rates USNA as Underperform.
- USNA PE ratio analysis and historical PE chart
- USNA PS ratio (Price-to-Sales) history and trend
- USNA intrinsic value — DCF, Graham Number, EPV models
- USNA stock price prediction 2025 2026 2027 2028 2029 2030
- USNA fair value vs current price
- USNA insider transactions and insider buying
- Is USNA undervalued or overvalued?
- USANA Health Sciences Inc financial analysis — revenue, earnings, cash flow
- USNA Piotroski F-Score and Altman Z-Score
- USNA analyst price target and Smart Rating
USANA Health Sciences Inc
📊 No data available
Try selecting a different time range
USNA Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · USANA Health Sciences Inc (USNA)
USNA trades 432% above its Graham fair value of $3.94, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
USANA Health Sciences Inc (USNA) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/sales, price/book. Concerns around return on equity and operating margin. Fundamentals are solid but monitor weak areas for improvement.
USANA Health Sciences Inc (USNA) Key Strengths (4)
Growing significantly faster than its price suggests
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
57.87% held by institutions, strong professional interest
Supporting Valuation Data
USANA Health Sciences Inc (USNA) Areas to Watch (6)
Earnings declining -3.70%, profits shrinking
Very low returns on shareholder equity
Very thin margins with limited operational efficiency
Very thin margins, barely profitable
Modest revenue growth at 5.90%
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
USANA Health Sciences Inc (USNA) Detailed Analysis Report
Overall Assessment
This company scores 54/100 in our Smart Analysis, earning a C- grade. Out of 10 metrics analyzed, 4 register as strengths (avg 9.5/10) while 6 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Price/Sales, Price/Book. Valuation metrics including PEG Ratio (0.70), Price/Sales (0.34), Price/Book (0.59) suggest the stock is attractively priced.
The Bear Case
The primary concerns are EPS Growth, Return on Equity, Operating Margin. Growth concerns include Revenue Growth at 5.90%, EPS Growth at -3.70%, which may limit upside. Profitability pressure is visible in Return on Equity at 1.96%, Operating Margin at 7.63%, Profit Margin at 1.16%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 1.96% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 5.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, Price/Sales) and negatives (EPS Growth, Return on Equity). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
USNA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
USNA's Price-to-Sales ratio of 0.34x sits near its historical average of 0.36x (14th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 19% below its historical high of 0.42x set in Mar 2026, and 0% above its historical low of 0.34x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~0.4x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for USANA Health Sciences Inc (USNA) · CONSUMER DEFENSIVE › PACKAGED FOODS
The Big Picture
USANA Health Sciences Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 925M with 6% growth year-over-year. Profit margins are thin at 1.2%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 2.0% suggests the company isn't efficiently converting equity into profits.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Margin expansion: can USANA Health Sciences Inc push profit margins above 15% as the business scales?
Sector dynamics: monitor PACKAGED FOODS industry trends, competitive moves, and regulatory changes that could impact USANA Health Sciences Inc.
Bottom Line
USANA Health Sciences Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(115 last 3 months)
| Insider | Type | Shares |
|---|---|---|
FULLER, GILBERT A Director | Sell | -1,058 |
| Insider | Type | Shares |
|---|---|---|
BENEDICT, PETER CHIEF INFORMATION OFFICER | Sell | -4,553 |
| Insider | Type | Shares |
|---|---|---|
FOUKAS, JOSHUA CHIEF LEGAL OFFICER | Sell | -4,461 |
Data sourced from SEC Form 4 filings
Last updated: 11:32:41 AM
About USANA Health Sciences Inc(USNA)
NYSE
CONSUMER DEFENSIVE
PACKAGED FOODS
USA
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company is headquartered in Salt Lake City, Utah.